Search Results
Apr 15, 2026, 15:00 ET Perceptive Discovery Announces Strategic Partnership with MH3D and Launch of α-Sight™ to Advance Alpha Radiopharmaceutical Imaging
Huang, CEO and Founder at MH3D.α-Sight™ supports a range of applications, including biodistribution studies, tumor targeting validation, and PK/PD assessment, helping accelerate candidate selection and de-risk radioligand therapy development programs.About Perceptive DiscoveryPerceptive
More news about: Perceptive Discovery
Apr 15, 2026, 12:03 ET Adimab Collaborator GSK Receives Additional Marketing Approval for Depemokimab
tools.Other commercial products containing molecules from Adimab include:Innovent's TYVYT® (sintilimab injection), a PD1 program approved in China for the treatment of multiple cancers.Innovent's SINTBILO® (tafolecimab injection), a PCSK9 program approved
More news about: Adimab, LLC
Apr 15, 2026, 09:00 ET Cala Announces FDA Clearance of its Next Generation TAPS Therapy Wearable Device for Essential Tremor and Parkinson's Disease
kIQ® Plus system, the next-generation of its wearable neurostimulation device for action hand tremor in essential tremor (ET) and Parkinson's disease (PD). Cala kIQ Plus is the latest advancement in TAPS® technology - introducing new therapy modes and adaptive calibration designed to optimize
More news about: Cala Health
Apr 15, 2026, 08:00 ET Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
inhibitor being developed across oncology indications, including advanced breast cancer;NDL2, a novel PD-L1 protein degrader platform designed to target intracellular and nuclear PD-L1 biology; andMSETC, a first-in-class SETDB1-targeted epigenetic program aimed at reversing immune evasion
More news about: Kazia Therapeutics Limited
Apr 15, 2026, 08:00 ET ImmunoGenesis Announces Poster Presentation at AACR 2026 Annual Meeting
immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2. IMGS-001 is currently in a phase 1a/b clinical trial for the treatment of immune-excluded tumors, which account for more than half of all cancers.
More news about: Immunogenesis Inc.
Apr 15, 2026, 07:00 ET Power Metallic Intercepts 27.10 Meters of 2.17% CuEqRec¹, including 4.76 Meters of 10.43% CuEqRec¹ in Hole 26-050 at Lion
possibly being fault controlled. All these holes (Figure 1) encountered low grade mineralization, Cu (up to 0.22%), Au (up to 0.20 g/t Au), Pd (up to 0.60 g/t Pd), and Pt (0.21 g/t Pt) and effectively define the eastern boundary of the Lion Zone.Holes PML-26-060 and 064 were drilled 400-450 meters
More news about: Power Metallic Mines Inc.
Apr 15, 2026, 03:30 ET ENGWE Launches ZIP Folding E-Bike Alongside 12th Anniversary Celebration Offers
flight of stairs, tuck under a desk, or slip into a train carriage. Its 36V 10Ah removable battery provides up to 120 km per charge and doubles as a PD3.0 USB-C power bank, keeping your devices powered while on the move.Comfort, control, and safety are built into every ride. ZIP features a torque
More news about: ENGWE
Apr 15, 2026, 03:30 ET ENGWE bringt das faltbare E-Bike ZIP auf den Markt und bietet anlässlich seines 12-jährigen Bestehens Jubiläumsangebote an
einen Zugabteil schieben lässt. Sein herausnehmbarer 36-V-Akku mit 10 Ah bietet eine Reichweite von bis zu 120 km pro Ladung und dient gleichzeitig als PD 3.0-USB-C-Powerbank, sodass Ihre Geräte auch unterwegs mit Strom versorgt werden.Komfort, Kontrolle und Sicherheit bei jeder Fahrt. Das ZIP verfügt
More news about: ENGWE
Apr 15, 2026, 03:30 ET ENGWE lanza la bicicleta eléctrica plegable ZIP junto con ofertas especiales para celebrar su 12º aniversario
en un vagón de tren. Su batería extraíble de 36 V y 10 Ah ofrece hasta 120 km de autonomía por carga y, además, funciona como batería externa USB-C PD3.0, manteniendo tus dispositivos cargados mientras te desplazas.Comodidad, control y seguridad en cada trayecto. La ZIP incorpora un sensor de par,
More news about: ENGWE
Apr 15, 2026, 03:30 ET ENGWE lance le vélo électrique pliant ZIP en plus des offres qu'elle propose dans le cadre de son 12e anniversaire.
wagon de train. Sa batterie amovible de 36 V 10 Ah permet de parcourir jusqu'à 120 km par charge et fonctionne également comme batterie externe USB-C PD3.0, pour que vos dispositifs puissent être rechargés lors de vos déplacements.Le confort, le contrôle et la sécurité sont intégrés à chaque trajet.
More news about: ENGWE
Apr 14, 2026, 20:00 ET SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
disease subtyping of PD and MSA, as well as potential imaging support for subject screening and efficacy evaluation in clinical trials of related therapeutic drugs.According to data from the Global Burden of Disease (GBD) Study 1990–2021, there were approximately 11.8 million PD patients worldwide
More news about: Mabwell
Apr 14, 2026, 20:00 ET 邁威生物孵化公司思努賽生物 α-syn PET示蹤劑SST001獲NMPA批准開展臨床試驗
新范式，對帕金森病核心病理蛋白 α-synuclein 聚集體進行了大量的結構解析及與配體互作機制研究，最終獲得臨床候選分子18F-FD4（研發代號：SST001），目前已經過數十例 IIT 試驗展現出高度的靈敏性和良好的特異性識別能力，有望為 PD、多系統萎縮（MSA）等疾病診斷和治療帶來顛覆性的解決方案。關於邁威生物邁威生物 (688062.SH) 是一家全產業鏈布局的創新型生物制藥公司，始終秉承「讓創新從夢想變成現實」的願景，踐行「探索生命，惠及健康」的使命，通過源頭創新，為患者提供療效更好、可及性更強的生物創新藥，滿足全球未被滿足的臨床需求。2017
More news about: 邁威生物
Apr 14, 2026, 05:22 ET American Parkinson Disease Association Kicks Off 2026 Optimism Walk Series
Optimism Walks are a powerful way to bring local communities together, raise vital funds, and remind everyone impacted by PD that they are not alone."APDA offers a wide range of PD programs, resources, education, and support. To learn more, visit
More news about: American Parkinson Disease Association, Inc.
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
SKB264-II-06/MK-2870-002 of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), in combination with MSD's[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[2]), were selected for oral presentation at the 2026 Society of Gynecologic Oncology
More news about: Kelun-Biotech
Apr 13, 2026, 17:05 ET Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
(paxalisib) altering gene expression programs that drive tumor growth and immune suppressionProtein-level control (PD-L1 degrader platform, NDL2) eliminating intracellular PD-L1 and overcoming resistance mechanisms beyond antibody-based therapiesThis integrated approach is designed
More news about: Kazia Therapeutics Limited
Apr 13, 2026, 10:52 ET Florida Cancer Specialists & Research Institute Contributes to Milestone that Expands Treatment Options For Patients With Recurrent Ovarian Cancer
slow the progression of certain ovarian cancers, improving outcomes and extending lives for patients with cancers that have a specific marker called PD-L1 (present in approximately 75% of cases) and no longer respond to standard platinum-based chemotherapy.
More news about: Florida Cancer Specialists & Research Institute
Apr 13, 2026, 06:00 ET IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
real-world clinical practice that consists of 103 patients. The ICT arm was composed of 76% (n=78) ipilimumab plus nivolumab (anti-CTLA-4/PD-1) and 24% (n=25) pembrolizumab (anti-PD-1). The primary endpoint is median PFS as assessed by BICR, which will be used to support an initial NDA submission in the United
More news about: IDEAYA Biosciences, Inc.
Apr 13, 2026, 00:00 ET AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
AnBogen is actively advancing a Phase 1/2 global multi-center clinical trial (NCT07244705) for Imofinostat in combination with Tislelizumab (an anti-PD-1 monoclonal antibody provided by BeOne Medicines under a clinical drug supply agreement) and an anti-angiogenic agent for advanced CRC.This triple
More news about: Anbogen Therapeutics
Apr 13, 2026, 00:00 ET AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
AnBogen is actively advancing a Phase 1/2 global multi-center clinical trial (NCT07244705) for Imofinostat in combination with Tislelizumab (an anti-PD-1 monoclonal antibody provided by BeOne Medicines under a clinical drug supply agreement) and an anti-angiogenic agent for advanced CRC.This triple
More news about: Anbogen Therapeutics
Apr 10, 2026, 13:57 ET APDA Applauds Seating of the National Parkinson's Plan Advisory Council
together a broad range of Parkinson's disease (PD) expertise and lived experience. APDA is thrilled with the selections of Cathi Ann Thomas, MS, RN, CNRN and David G. Standaert, MD, PhD – two dedicated, long-standing APDA partners and fierce advocates for the PD community.
More news about: American Parkinson Disease Association, Inc.
Apr 10, 2026, 08:30 ET MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks. The study will assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and
More news about: MetaVia Inc.
Apr 09, 2026, 14:31 ET Lancaster Sees Sharp Drop in Collisions as Increased Traffic Enforcement Delivers Results
fewer injuries, fewer lives disrupted, and safer streets for our residents. This is also a credit to the way our hybrid model is working, with Lancaster PD and LASD continuing to work together to deliver stronger public safety outcomes for our community."The report credits the addition of extra Lancaster
More news about: City of Lancaster
Apr 09, 2026, 10:55 ET Why Smart Money Is Chasing Polymetallic Deposits Right Now
the Costerfield Operation in central Victoria, Australia, with high-grade intercepts including 132.2 g/t gold and 19.8% antimony over 1.94 metres in PD222 and 267.5 g/t gold and 5.6% antimony over 2.3 metres in BC464. The Kendal system is the antimony-rich, up-dip continuation of the Youle and Shepherd
More news about: USA News Group
Apr 09, 2026, 07:45 ET Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
An Assessment of AcutePharmacodynamic Drug-DrugInteractions (PD-DDIs) BetweenCannabidiol (CBD) andCenobamate (CNB) in a MouseModel of Generalized TonicSeizures
More news about: Jazz Pharmaceuticals plc
Apr 09, 2026, 07:30 ET Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
αSyn-aggregation which induces a chronic inflammatory state that is associated with PD disease progression and severity. Subject to the regulatory advice we are now seeking, we are planning to advance Aramchol to a PoC Ph1b/2 studies in PD patients in H2 2026."Ronen Eavri, Co-founder & CEO of Barcode
More news about: Galmed Pharmaceuticals Ltd.